ReviewFrontiers in dental medicine2026
Immune suppression, HLA-risk and potential future immune based targets of oral leukoplakia progression.
Review in Frontiers in dental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral leukoplakia (OL) is the most common oral potentially malignant disorder and carries a non-trivial risk of malignant transformation. Biomarkers are sought to aid in identifying lesions with high risk for malignant transformation, yet none are currently validated. Recent success of immune based therapies in head and neck oncology highlights immune involvement in the progression of these diseases. The differential expression of classical and non-classical HLA molecules in oral leukoplakia are thought to contribute to their malignant transformation. To better evaluate the role HLA plays in oral pre-malignant lesions, a scoping review was performed. Methods: A scoping review was conducted in accordance with the PRISMA guidelines across PubMed, EMBASE, and Web of Science. 293 studies were reviewed from 1989 to 2025. Results: 15 studies were screened by title, then 5 original research abstracts were included. Samples studied ranged from Conclusion: The upregulation of non-classical HLA molecules, particularly HLA-G, HLA-E, and circHLA-C in oral leukoplakia, suggests an immunologic shift, potentially facilitating tumor immune evasion in oral leukoplakic lesions. HLA expression may serve as a potential biomarker for identifying pre-malignant oral lesions at increased risk of malignant transformation. Also, circHLA-C may provide a target for therapeutic intervention in high-risk oral premalignant lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.